Precigen, Inc.

NASDAQ:PGEN

Biotechnology

Healthcare
$4.27 -2.08%

-$0.10 today

Market cap
$1.53B
Beta
1.06
P/E (TTM)
-7.1
EPS (TTM)
-$0.65
52W Low $1.39High $5.47

Volume 4.27M

Average 4.72M

PGEN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Precigen, Inc.NASDAQ: PGEN

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $3.58M rose 118.6% year over year, ahead of the +42.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 19.1% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Stock-based compensation amounted to 112.2% of revenue in FY2025, down 129.1 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +118.6% holds above the trailing-twelve-month pace of +42.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.58M+19.1% QoQ
Last fiscal yearDec 2025
$10.87M+14.7% YoY
LTMJun 2026
$13.14M+42.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+118.6%——
1 year+14.7%——
3-year CAGR+2.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.87M USD
Year-over-year change
+14.7%
4-year CAGR
-6.0%

Stock-Based Compensation vs competitors

How PGEN compares with its peers on the latest reported figures

  • PGEN's LTM Jun 2026 stock-based compensation of $13.14M is the 5th largest of the 8 companies compared; the peer median is $34.64M.
  • Its year-over-year change of +42.2% is the highest of 8, against a peer median of -8.8%.
  • Stock-based compensation amounts to 15.3% of revenue for PGEN, versus a peer median of 48.4%.
PGEN Competitors Peer median
Stock-Based Compensation for PGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M +2.8%+19.1%220.8%
CRSPCRISPR Therapeutics AGLTM Sep 2026$69.68M -8.8%-9.5%276.8%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M -20.0%+6.1%—
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
PGENPrecigen, Inc.LTM Jun 2026$13.14M +42.2%+2.1%15.3%
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M -45.7%-30.1%23.6%
DTILPrecision BioSciences, Inc.LTM Mar 2026$8.91M -28.8%-19.0%19.8%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$8.33M +7.1%+52.3%57.3%
Peer median (excluding PGEN) $34.64M-8.8%-5.4%48.4%

Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(92.17M)28.32M(95.9M)(126.24M)(250.64M)
Depreciation & Amortization13.76M10.77M6.67M4.53M3.2M
Deferred Income Tax(167K)(150K)(479K)(1.8M)0
Stock-Based Compensation13.9M10.21M9.89M9.47M10.87M
Change in Working Capital(804K)(35.7M)17.07M4.52M6.62M
Accounts Receivables(6.56M)(13.51M)12.23M414K(3.2M)
Inventory(1.9M)2.34M00(9.21M)
Accounts Payables420K379K(2.42M)1.55M8.77M
Other Working Capital7.24M(24.91M)7.26M2.56M10.26M
Other Non-Cash Items9.7M(78.48M)(4.17M)41.34M142.12M
Operating Cash Flow(55.77M)(65.05M)(66.93M)(68.17M)(87.83M)
Capital Expenditures(7.25M)(4.92M)(1.54M)(8.58M)(2M)
Acquisitions (Net)00000
Purchases of Investments(174.22M)0(185.03M)(187.21M)(208.01M)
Sales of Investments100.17M68.44M183.38M175.02M208.47M
Other Investing Activities6.76M162.9M98K60K0
Investing Cash Flow(74.54M)226.42M(3.09M)(20.71M)(1.54M)
Debt Repayment(466K)(155.29M)(43.22M)092.82M
Common Stock Issued121.05M072.81M31.24M310K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities608K1K0346K(3.08M)
Financing Cash Flow121.19M(155.29M)29.59M110.58M90.05M
Effect of Forex Changes217K(827K)(320K)(27K)35K
Net Change in Cash(8.91M)5.25M(40.75M)21.67M717K
Free Cash Flow(63.02M)(69.97M)(68.47M)(76.76M)(89.83M)

Precigen, Inc.

NASDAQ:PGEN

Intrinsic Alpha fair value

Locked

Current Price

$4.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.